The importance of sodium/iodide symporter (NIS) for thyroid cancer management

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 5, 2007, Pages 672-682

  Carvalho, Denise P ^a   Ferreira, Andrea C F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cancer; Gene transfer; Iodide uptake; NIS; Radioiodine; Thyroid

Indexed keywords

EID: 35348857500     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000500004     Document Type: Review

References (102)

1. Baumann E. Uber den Jodgehalt der Schilddrüsen Von Menchen und Tieren. Hoppe Seylers Z Physiol Chem 1896;22:1-17.
2. Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem 1948;174:555-64.
3. 2-generating activity and thyroperoxidase in toxic diffuse goiters. Eur J Endocrinol 2002;147(3):293-8.
4. Heufelder AE, Morgenthaler N, Schipper ML, Joba W. Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies. Thyroid 2001;11:839-47.
5. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:485-60.
6. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339-45.
7. - Symporter - mechanism, stoichiometry, and specificity. J Biol Chem 1997;272:27230-8.
8. Scott DA, Wang R, Kreman TM, Sheffield VC, Karniski LP. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet 1999;21(4):440-3.
9. van den Hove MF, Croizet-Berger K, Jouret F, Guggino SE, Guggino WB, Devuyst O, et al. The loss of the chloride channel, ClC-5, delays apical iodide efflux and induces a euthyroid goiter in the mouse thyroid gland. Endocrinology 2006;147:1287-96.
10. th ed. Philadelphia: Lippincott Williams & Wilkins, 2000. pp. 61-85.
11. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003;24:48-77.
12. - symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001;86:2697-700.
13. - symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 2003;213(1):59-70.
14. Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001;276:21458-63.
15. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 2006;155(4):495-512.
16. Spitzweg C, Morris JC. Approaches to gene therapy with sodium/iodide symporter. Exp Clin Endocrinol 2001;109:56-9.
17. Reizer J, Reizer A, Saier MH Jr. A functional superfamily of sodium/solute symporters. Biochim Biophys Acta 1994;1197(2):133-66.
18. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997;138(8):3555-8.
19. - symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci USA 1997;94:5568-73.
20. - symporter (NIS). Implications for its secondary structure model. J Biol Chem 1998;273:22657-63.
21. - symporter in patients with iodide transport defect. J Clin Endocrinol Metab 1998;83(8):2940-3.
22. - symporter activity requires a small and uncharged amino acid residue at position 395. Mol Endocrinol 2002;16(8):1893-902.
23. - transporting cultured thyroid cells. Proc Natl Acad Sci USA 1994;91:3789-93.
24. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 1999;19(3):2051-60.
25. Tonacchera M, Viacava P, Agretti P, de Marco G, Perri A, di Cosmo C, et al. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. J Clin Endocrinol Metab 2002;87:352-7.
26. Ferreira AC, Lima LP, Araújo RL, Muller G, Rocha RP, Rosenthal D, et al. Rapid regulation of thyroid sodium-iodide symporter activity by thyrotrophin and iodine. J Endocrinol 2005;184(1):69-76.
27. Braverman LE, Ingbar SH. Changes in thyroidal function during adaptation to large doses of iodide. J Clin Invest 1963;42:1216-31.
28. Eng PHK, Cardona GR, Fang SL, Previti M, Alex S, Carrasco N, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999;140:3404-10.
29. Grollman EF, Smolar A, Ommaya A, Tombaccini D, Santisteban P. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology 1986;118:2477-82.
30. Pisarev MA. Thyroid autoregulation. J Endocrinol Invest 1985;8(5):475-84.
31. Pereira A, Braekman JC, Dumont JE, Boeynaems JM. Identification of a major iodolipid from the horse thyroid gland as 2-iodohexadecanal. J Biol Chem 1990;265(28):17018-25.
32. Fukuda H, Greer M, Roberts L, Allen CE, Critcholow V, Wilson M. Nyctohemeral and sex-related variations in plasma thyrotropin, thyroxinne, and triiodotironine. Endocrinology 1975;97:1424-30.
33. Urban RJ. Neuroendocrinology of aging in the male and female. Endocrinol Metab Clin North Am 1992;21:921-31.
34. Furlanetto TW, Nguyen LQ, Jameson JL. Estrogen increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5. Endocrinology 1999;140:5705-11.
35. Chen HJ, Walfish PG. Effects of age and ovarian function on the pituitary-thyroid system in female rats. J Endocrinol 1978;78:225-32.
36. Christianson D, Roti E, Vagenakis AG, Braverman LE. The sex-related difference in serum thyrotropin concentration is androgen mediated. Endocrinology 1981;108:529-35.
37. Fisher JS, D'Angelo SA. Stimulatory and inhibitory action of estrogen on TSH secretion. Endocrinology 1971;88:687-91.
38. Lisboa PC, Curty FH, Moreira RM, Pazos-Moura CC. Effects of estradiol benzoate on 5′- iodotironine deiodinase activities in female rat anterior pituitary gland, liver and thyroid gland. Braz J Med Biol Res 1997;30:1479-84.
39. Boccabella AV, Alger EA. Influence of estradiol on thyroid: serum radioiodine concentration ratios of gonadectomized and hypophysectomized rats. Endocrinology 1964;74:680-8.
40. Hiasa Y, Kitahori Y, Yane K, Nishioka H, Nakahashi K, Konishi N, et al. Establishment of estrogen receptor-positive transplantable rat thyroid tumor cell lines in vivo. Cancer Res 1993;53:4408-12.
41. Banu SK, Govindarajulu P, Aruldhas MM. Testosterone and estradiol up-regulate androgen and estrogen receptors in immature and adult rat thyroid glands in vivo. Steroids 2002;67:1007-14.
42. Lima LP, Barros IA, Lisboa PC, Araújo RL, Silva AC, Rosenthal D, et al. Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. Steroids 2006;71(8):653-9.
43. Marcus M, Coulton AM. Fat-soluble vitamins A, K, E. In: Hadman JG, Limbird LE, Gilman AG (eds). Goodman and Gilmamn's The Pharmacologic Basis of Therapeutics. Mc Graw Hill, 2000. pp. 1773-92.
44. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab. 2000;85:2889-96.
45. Schmutzler C, Winzer R, Maissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of function symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-8.
46. Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-8.
47. Schmutzler C, Brtko J, Bienert K, Köhrle J. Effects of retinoids and role of retinoic receptor in human thyroid carcinomas and cell lines derived there from. Exp Clin Endocrinol Diabetes 1996;104(suppl 4):16-9.
48. Van Herle AJ, Agatep ML, Padua DN, Totanes TL, Canlapan DV, Van Herle HML, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990;71:755-63.
49. Simon D, Köhrle J, Schmutzler C, Mainz K, Reiners C, Röher HD. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996;104(suppl 4):13-5.
50. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998;22:569-74.
51. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;39:1903-6.
52. Schmutzler C, Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000;10:393-405.
53. Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med 2002;29:775-82.
54. Grüning T, Tiepolts C, Zöphel K, Bradow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003;148:395-402.
55. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004;27(4):334-9.
56. Coelho SM, Vaisman M, Carvalho DP. Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 2005;11(19):2525-31.
57. Monzani F, Caraccio N, Casolaro A, Lombardo F, Moscato G, Murri L, et al. Long-term interferon β-1b therapy for MS: is routine thyroid assessment always useful? Neurology 2000;22:549-52.
58. Rotondi M, Mazziotti G, Biondi B, Manganella G, Del Buono AD, Montella P, et al. Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease. J Endocrinol Invest 2000;23(5):321-4.
59. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, et al. Thyroid function and autoimmunity during interferon β-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86(8):3525- 32.
60. Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005;90(2):1156-62.
61. Ajjan RA, Watson PF, Findlay C, Metcalfe RA, Crisp M, Ludgate M, et al. The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. J Endocrinol 1998;158(3):351-8.
62. Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999;9(8):821-30.
63. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;25;389(6649):349-52.
64. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20(8):615-26.
65. Katan-Khaykovich Y, Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev 2002;16(6):743-52.
66. Davie JR. MSK1 and MSK2 mediate mitogen- and stress-induced phosphorylation of histone H3: a controversy resolved. Sci STKE 2003;12(195):PE33.
67. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86(7):3430-5.
68. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002;132(6):984-90.
69. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004;145(6):2865-75.
70. - symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004;89(2):1006-9.
71. Kitazono M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86(2):834-40.
72. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005;146(9):3967-74.
73. Schmitt TL, Espinoza CR, Loos U. Transcriptional regulation of the human sodium/iodide symporter gene by Pax8 and TTF-1. Exp Clin Endocrinol Diabetes 2001;109(1):27-31.
74. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 2002;16(10):2266-82.
75. Puppin C, Presta I, D'Elia AV, Tell G, Arturi F, Russo D, et al. Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. Mol Cell Endocrinol 2004;214(1-2):117-25.
76. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994;17:4744-9.
77. Pasca di Magliano M, Di Lauro R, Tannini M. PAX8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 2000;221:13144-9.
78. Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer 2005;5(1):80.
79. Suzuki K, Lavaroni S, Mori A, Ohta M, Saito J, Pietrarelli M, et al. Autoregulation of thyroid-specific gene transcription by thyroglobulin. Proc Natl Acad Sci USA 1998;95(14):8251-6.
80. Dohan O, De la Vieja A, Carrasco N. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells. Mol Endocrinol 2006;20(5):1121-37.
81. De La Vieja A, Ginter CS, Carrasco N. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number. J Cell Sci 2004;117(Pt 5):677-87.
82. - symporter. Mol Endocrinol 2005;19(11):2847-58.
83. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, et al. Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol 2004;165(1):25-34.
84. Mian C, Lacroix L, Alzieu L, Nocera M, Talbot M, Bidart JM, et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 2001;11(9):825-30.
85. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97(5):418-28.
86. Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY, et al. Development of reverse transcription-competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter. Thyroid 1999;9(4):405-9.
87. - symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998;139(10):4416-9.
88. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83(7):2493-6.
89. Dohan O, Carrasco N. Thyroidal iodide transport and thyroid cancer. Cancer Treat Res 2004;122:221-36.
90. Cho JY. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther 2002;2(4):393-402.
91. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59(3):661-8.
92. - symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000;7(9):740-9.
93. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 2006;91(6):2389-95.
94. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003;63(22):7840-4.
95. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current status and future prospects. Thyroid 2004;14(6):424-34.
96. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8(20):1524-31.
97. Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2005;90(8):4457-64.
98. 124I positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol 2006;8(1):16-23.
99. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by Na/I symporter-expressing tissues in vivo. J Nucl Med 2004;45(3):500-7.
100. Dadachova E, Nguyen A, Lin EY, Gnatovskiy L, Lu P, Pollard JW. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol 2005;32(7):695-700.
101. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002;29(1):13-8.
102. Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002;29(7):842-54.